

Thursday 4th November 2010

0830 - 1030	Primary Care & IMSCC Joint Plenary Session	
<i>Session Chairs: John Thompson, Axel Hauschild</i>		Parkside Auditorium
0840 - 0910	Risk factors for melanoma <i>Bruce Armstrong</i>	
0910 - 0940	Melanoma Biology Unmasked <i>Hensin Tsao</i>	
0940 - 1015	Melanoma and personalised medicine <i>Boris Bastian</i>	
1015 - 1030	Discussion	
1030 - 1100	Morning Tea	
1100 - 1300	1100 - 1300	Diagnosis and Staging
	<i>Session Chairs: Alistair Cochran, Graham Stevens</i>	
	1100 - 1120	Evidence for diagnostic techniques in primary melanoma <i>Josep Malvehy</i>
	1120 - 1220	Lentigo Maligna: evolving techniques for assessment and management
	Parkside 110 A & B Combined	
	1120 - 1132	Lentigo maligna: minimal criteria for pathological diagnosis <i>Martin Mihm</i>
	1132 - 1140	Confocal diagnosis of lentigo maligna <i>Pascale Guitera</i>
	1140 - 1148	Efficacy of imiquimod 5% cream for lentigo maligna as assessed following complete excision - a study of 43 patients <i>Martin Haskett</i>
	1150 - 1200	Radiotherapy for lentigo maligna <i>Angela Hong</i>
	1200 - 1210	Surgical management of lentigo maligna <i>Ciaran Healy</i>
	1210 - 1220	What is the best treatment for lentigo maligna?

		Moderated panel discussion	
	1220 - 1300	Sentinel Node Biopsy	
	<i>Session Chairs: Claus Garbe, Alessandro Testori</i>		Parkside 110 A & B Combined
	1220 - 1230	Technical Advances	
		<u>Omgo Nieweg</u>	
	1230 - 1240	Is sentinel node biopsy 'standard of care' for melanoma in 2010?	
		<u>Vernon Sondak</u>	
	1240 - 1250	Who should have sentinel node biopsy and who should not?	
		<u>Daniel Coit</u>	
	1015 - 1030	Discussion	
	1100 - 1200	Informatics: Melanoma Databases & Digital Patient Records	
	<i>Session Chairs: Graham Mann, Kerwin Shannon</i>		Parkside G07
	1100 - 1115	Development of informatics at MIA	
		<u>Jonathan Stretch</u>	
	1115 - 1130	Database management in the UK	
		<u>Katherine Acland</u>	
	1130 - 1145	Database management in the US	
		<u>Jane Messina</u>	
	1145 - 1200	Panel Discussion	
	1200 - 1300	Rationalising melanoma management: comparative effectiveness research	
	<i>Session Chairs: Susan Neuhaus, David Ollila</i>		Parkside G07
	1200 - 1210	Economic considerations in melanoma care	
		<u>Rachael Morton</u>	
	1210 - 1220	Economic issues facing melanoma services in the US	
		<u>Jeffrey Gershenwald</u>	
	1220 - 1230	Health effectiveness modelling and the impact of imaging investigations	
		<u>Taryn Bessen</u>	
	1230 - 1240	The burden of follow-up: who should a melanoma unit see?	
		<u>Mark Smithers</u>	
1100 - 1300			

	1240 - 1250	Is melanoma follow up cost effective?	
		<u>Harald Hoekstra</u>	
	1250 - 1300	Discussion	
1300 - 1400	Multidisciplinary team meeting – Lunch with the Professors		
	Chairs: Rick Kefford, Vernon Sondak		
1400 - 1530	Pathology in multidisciplinary melanoma care in the molecular Era		
	<i>Session Chairs: Richard Scolyer, Martin Mihm</i>		Parkside 110 A & B Combined
1400 - 1530	1400 - 1415	The role of pathology review in multidisciplinary melanoma care	
		<u>Jane Messina</u>	
	1415 - 1430	Approaches to the diagnosis and management of Patients with histopathologically ambiguous primary melanocytic tumours	
		<u>Klaus Busam</u>	
	1430 - 1445	The role of FISH & CGH in the diagnosis of melanocytic tumours	
		<u>Pedram Gerami</u>	
	1445 - 1500	Tissue biomarkers for melanoma prognosis in 2010	
		<u>Bonnie Gould Rothberg</u>	
	1500 - 1515	Maximising the value of melanoma biospecimen bank	
		<u>Graham Mann</u>	
	1515 - 1530	Discussion	
1400 - 1530	Quality Assurance in Melanoma Surgery		
	<i>Session Chairs: Andrew Spillane, Dan Coit</i>		Parkside G07
1400 - 1530	1400 - 1410	QA In Melanoma Surgery: how do we provide the right care to the right patient at the right time?	
		<u>Vernon Sondak</u>	
	1410 - 1420	What we do to guarantee QA	
		<u>Jeffrey Gershenwald</u>	
	1420 - 1430	Quality assurance in the Netherlands	
		<u>Omgo Nieweg</u>	
	1430 - 1440	Quality Assurance in Melanoma Surgery - the evolving Melanoma Institute Australia (MIA) experience	
		<u>Andrew Spillane</u>	

	1440 - 1530	Discussion	
1530 - 1600		Afternoon Tea	
1600 - 1730		Advances in management of locoregional disease – Session Proudly Sponsored by Provectus	
	<i>Session Chairs: Mark Smithers, Carlo Riccardo Rossi</i>		Parkside 110 A & B Combined
	1600 - 1610	Electrochemotherapy with bleomycin: a local treatment with possible systemic implications <i>Alessandro Testori</i>	
	1610 - 1620	Percutaneous hepatic perfusion (Delcath procedure) for melanoma metastases to the liver <i>Jonathan Zager</i>	
	1620 - 1630	Phase I Evaluation of the intralesional administration of the oncolytic picornavirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma <i>Darren Shafren</i>	
	1630 - 1640	Chemoablation of metastatic melanoma with intralesional PV-10 <i>Sanjiv Agarwala</i>	
1600 - 1730	1640 - 1650	Isolated limb infusion <i>Andrew Barbour</i>	
	1650 - 1700	OncoVEXGM-CSF: Phase 2 data and update on the ongoing pivotal Phase 3 trial <i>Robert Coffin</i>	
	1700 - 1710	Topical diphencyprone immunotherapy for extensive cutaneous metastatic melanoma <i>Diona Damian</i>	
	1710 - 1730	Discussion	
1600 - 1730		Supportive Care	
	<i>Session Chairs: Fran Boyle, Phyllis Butow</i>		Parkside G07
	1600 - 1615	Psychosocial care for melanoma patients: what do we know? <i>Phyllis Butow</i>	
	1615 - 1630	Supportive care needs of patients at high risk of melanoma: current research. <i>Nadine Kasparian</i>	
1600 - 1730	1630 - 1645	Improving the measurement of Quality of Life in melanoma patients <i>Julie Winstanley</i>	
	1645 - 1700	Working with patients and families - fostering realistic optimism	

	<u>Stewart Dunn</u>
1700 - 1730	Discussion
1730 - 1830	Poster Session (IMSCC)
1830 - 1930	Keynote Address
<i>Session Chairs: Rick Kefford</i>	
	Parkside G07
1830 - 1930	Evolving melanoma therapeutics
	<u>Keith Flaherty</u>

Friday 5th November 2010

0715 - 0730	GSK Program: Adjuvant Therapy – What lies ahead
<i>Session Chairs: Richard Kefford & Peter Hersey</i>	
	Parkside 110A & 110B
0715 - 0730	What is the promise and risk of selective BRAF inhibitors in adjuvant therapy? <u>Lead discussants: Jeff Sosman, Reinhard Dummer</u>
0730 - 0745	How can we target immunotherapy more effectively? Biomarker studies <u>Lead discussants: Jonathan Cebon, Graham Mann, John Kirkwood</u>
0745 - 0800	What lies ahead in choice of antigens for immunotherapy? <u>Lead discussants: Rod Dunbar, Jurgen Becker</u>
0800 - 0815	Questions and Discussion
0830 - 1030	Targeted Therapies I
<i>Session Chairs: Dirk Schadendorf, Antoni Ribas</i>	
	Parkside Auditorium
0830 - 0900	Selective inhibition of oncogenic BRAF V600E/K/D by GSK2118436: Evidence of clinical activity in subjects with metastatic melanoma <u>Richard Kefford</u>
0900 - 0930	An open-label, multicenter phase 2 study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma <u>Jeff Sosman</u>
0930 - 1000	Feedback inhibition of RAF/MEK signalling <u>Neal Rosen</u>
1000 - 1030	BRAF/CRAF switching <u>Richard Marais</u>

* Program is current as at 27th October and is subject to change.

1030 - 1100		Morning Tea
1100 - 1300	1100 - 1200	Adjuvant therapies – Session Proudly Sponsored by MSD
	<i>Session Chairs: Freidagund Meier, Dirk Schadendorf</i>	
	Parkside 110 A & B Combined	
	1100 - 1112	PEG intron, Ipilimumab <i>Alexander Eggermont</i>
	1112 - 1124	MAGE-3A vaccine studies. Current studies: interferon <i>John Kirkwood</i>
	1124 - 1136	Current Studies <i>Axel Hauschild</i>
	1136 - 1148	Adjunctive radiotherapy trial <i>Michael Henderson</i>
	1148 - 1200	Discussion
	1200 - 1300	Management of Cerebral Disease
	<i>Session Chairs: John Kirkwood, Mark Middleton</i>	
	Parkside 110 A & B Combined	
	1200 - 1210	Role of resection <i>Brinda Shivalingham</i>
	1210 - 1220	The role of the gamma knife on cerebral melanoma metastases <i>Michael Izard</i>
	1220 - 1230	Whole brain radiotherapy following local treatment of 1-3 intracranial metastases of melanoma - a phase III trial <i>Gerald Fogarty</i>
1230 - 1245	Cerebral disease in the age of targeted therapy <i>Keith Flaherty</i>	
1245 - 1300	Discussion	
1100 - 1210		Surgical management
<i>Session Chairs: Jeffrey Gershenwald, Jonathan Stretch</i>		
Parkside G07		
1100 - 1107	Management of melanoma in Primary care in East of England <i>J. Garioch</i>	
1107 - 1114	Setting up an efficient and effective sentinel node biopsy service for malignant melanoma patients- the Norfolk and Norwich experience	

1100 - 1300		<u>M. Moncrieff</u>
	1114 - 1121	ODAM, A Novel Tight Junction Protein, Predicts Sentinel Node Metastasis in Cutaneous Melanoma
		<u>S. Gandhi</u>
	1121 - 1128	Preoperative Hybrid SPECT/CT detecting sentinel lymph nodes in cutaneous head and neck malignancies
		<u>J. Klode</u>
	1128 - 1135	Sentinel Node Positive Melanoma Patients- Is there a continued role for staging investigations prior to a completion lymphadenectomy?
		<u>J. Spillane</u>
	1135 - 1142	Disease-Specific Mortality in Sentinel Node-Negative Melanoma Patients
		<u>E. Whitman</u>
	1142 - 1149	Lymph node ratio should be recognised as a stratification factor in melanoma surgical trials
		<u>A. Spillane</u>
	1149 - 1156	Lymph node management of patients diagnosed with invasive melanoma in New South Wales
		<u>C. Madronio</u>
	1156 - 1203	Chronic Pain after Surgery for Malignant Melanoma
		<u>H. Hømyr</u>
	1203 - 1210	Discussion
1210 - 1300	Non Surgical Management	
<i>Session Chairs: Rick Essner, Catriona McNiell</i>		Parkside G07
1210 - 1217	Merkel cell Carcinoma : The Westmead hospital experience and management approach.	
	<u>J. Howle</u>	
1217 - 1234	Adoptive Transfer of Short-Term Cultured Tumor Infiltrating Lymphocytes in Metastatic Melanoma Patients: Clinical Results	
	<u>J. Schachter</u>	
1234 - 1241	L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemo-naïve stage IV melanoma patients.	
	<u>B. Weide</u>	
1241 - 1248	Expression of MAGE-A3 among stage IIIB-C melanoma patients: preliminary results of screening tests for the DERMA trial	

		<i>J. Grob</i>	
	1248 - 1300	Discussion	
1300 - 1400	BMS Lunch Symposium		
<i>Session Chairs: Peter Hersey</i>			Parkside 110 A & B Combined
	1300 - 1305	Introduction <i>Peter Hersey</i>	
	1305 - 1320	Cancer Vaccines. Successes and failures <i>Jonathan Cebon</i>	
	1320 - 1340	Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 <i>F. Stephen Hodi</i>	
		Discussion	
1400 - 1530	Merkel cell carcinoma		
<i>Session Chairs: Gerald Fogarty, Vernon Sondak</i>			Parkside 110 A & B Combined
1400 - 1530	1400 - 1420	What's new in Merkel cell carcinoma? <i>Jürgen Becker</i>	
	1420 - 1450	MCC Therapeutics Debate: What is the mainstay of MCC treatment in 2010? <i>Daniel Coit and Michael Poulsen</i>	
	1450 - 1500	Update: systemic therapies for MCC <i>Alex Guminski</i>	
	1500 - 1510	Towards prospective trials in MCC - the importance of multidisciplinary collaboration <i>George Hruby</i>	
	1510 - 1530	Panel Discussion	
1400 - 1530	Communication Workshop		
<i>Session Chairs: Fran Boyle</i>			Parkside G07
	1400 - 1530	Looking into the sun - staying healthy in melanoma care <i>Stewart Dunn</i>	
1530 - 1600	Afternoon Tea		
	1600 - 1630	What makes a melanoma centre?	
<i>Session Chairs: Josep Malvehy, Harald Hoekstra</i>			Parkside 110 A & B Combined
	1600 - 1610	What makes a melanoma centre?	

* Program is current as at 27th October and is subject to change.

1600 - 1730		<u>Vernon Sondak</u>	
	1610 - 1620	Melanoma in China	
		<u>Jun Guo</u>	
	1620 - 1630	Melanoma in Japan	
		<u>Hisashi Uhara</u>	
	1630 - 1700	Focus Group Reports	
			Parkside 110 A & B Combined
	1630 - 1635	Quality Assurance	
		<u>Andrew Spillane</u>	
	1635 - 1640	Informatics	
		<u>Jonathan Stretch</u>	
	1640 - 1645	Economics	
		<u>Susan Neuhaus</u>	
	1645 - 1650	Supportive Care	
		<u>Fran Boyle</u>	
	1650 - 1655	Web-based information for patients and carers	
		<u>Valerie Guild</u>	
	1655 - 1705	Discussion	
	1705 - 1740	Towards International Guides for Melanoma	
		<i>Session Chairs: Graham Stevens, Alistair Cochran</i>	Parkside 110 A & B Combined
1705 - 1712	NCNN guidelines		
	<u>Daniel Coit</u>		
1712 - 1719	European Guidelines		
	<u>Claus Garbe</u>		
1719 - 1726	How do we develop international guidelines? The Australian/New Zealand model		
	<u>John Thompson</u>		
1726 - 1735	Panel Discussion		
1735-1740	Cnetres meeting: closing remarks John Thompson		
1600 - 1700	Prevention and early detection		

<i>Session Chairs: Peter Soyer, Diona Damian</i>		Parkside G07
1600 - 1730	1600 - 1607	Personal, time-stamped dosimeter readings reveal that high UVR exposure doses are correlated to sun risk behaviour in non-outdoor workers <i><u>E. Thieden</u></i>
	1607 - 1614	Serum vitamin D levels in melanoma patients on follow up in Scotland <i><u>R. Mackie</u></i>
	1614 - 1621	Interdependence between body surface area and UVB dose in vitamin D production: A randomized controlled trial. <i><u>M. Boqh</u></i>
	1621 - 1628	Oxidative stress in human skin cells and its association with mitochondrial damage and skin cancer <i><u>M. Birch-Machin</u></i>
	1628 - 1635	Risk of non-melanoma cancer in CDKN2A carriers <i><u>B. Mukherjee</u></i>
	1635 - 1642	Early detection of melanoma based on Digital Follow-Up of high-risk patients. Ten years Spanish experience of a prospective surveillance. <i><u>C. Carrera</u></i>
	1642 - 1649	Seasonal variability in the diagnosis of primary cutaneous melanoma – a comparison of the Northern & Southern hemispheres <i><u>J. Kim</u></i>
	1649 - 1700	Discussion